Abstract library

13 results for "Mansoor".
#843 Lymph Node Involvement to Predict Survival in Pulmonary Neuroendocrine Tumors – A Single Center Experience
Introduction: Typical (TC) and Atypical carcinoid (AC) tumors are well-differentiated neuroendocrine tumors of the lung.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Vanessa E Clay
Authors: Clay V E, Stein R, Piarino E, Lam D, ...
Keywords: lung
#902 Chemotherapy for Advanced Neuroendocrine Tumors (NETs): Patient Selection Should be Independent of Primary Tumor Site
Introduction: Chemotherapy (CT) is used to treat patients (pts) with advanced poorly-differentiated (Pd); or well-differentiated (Wd) NETs with high-tumor burden (usually of pancreatic (pNET) origin).
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Angela Lamarca
#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience
Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Dr Zena Salih
Keywords: mibg
#1345 To Evaluate How the Outcome of Neuroendocrine Tumour (NET) Multidisciplinary Team (MDT) Meeting Decisions Are Conveyed to Patients at a ENETS Centre of Excellence (The Christie) and How This Service Can Be Further Improved
Introduction: It is recommended that people with cancer should be managed by an MDT and the outcomes should be communicated in a “timely manner”. However, it does not specify when this should be done, or by whom.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Christina Rigby
Authors: Rigby C, Mansoor W, Valle J, Hubner R, ...
#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours
Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#1499 Efficacy of the Combination of Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
Introduction: Limited treatment options exist for patients (pts) with advanced pulmonary carcinoids (PC). Capecitabine-temozolomide (CAPTEM) has demonstrated significant efficacy in pts with pancreatic neuroendocrine tumours. However, its role in PC remains unexplored.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
#1518 Significance of Preoperative FDG-PET/CT Scan in Patients with Pulmonary Carcinoid Tumours
Introduction: FDG uptake on PET/CT scan has been shown to be of prognostic significance in patients (pts) with metastatic neuroendocrine tumours (NET).
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Georgios Papaxoinis
#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).
Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Angela Lamarca
Keywords: immunotherapy
#1849 Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the Gastrointestinal (GI) Tract: Experience of a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence
Introduction: Knowledge of MANECs is limited
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Melissa Frizziero
#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).
Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr. Jorge Barriuso
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.